{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:15:27Z","timestamp":1790187327280,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) have heterogeneous outcomes; durable remissions are infrequently observed with standard approaches. Circulating tumor DNA (ctDNA) assessment is a sensitive, potentially prognostic tool in this setting. We assessed baseline ctDNA to identify patients with R\/R DLBCL at high risk of relapse after receiving polatuzumab vedotin and bendamustine plus rituximab (BR) or BR alone. Patients were transplant ineligible and had received \u22651 prior line of therapy. The ctDNA assay, based on a customized panel of recurrently mutated genes in DLBCL, measured mutant molecules per mL (MMPM) at baseline and end of treatment (EOT). Endpoints included progression-free survival (PFS) and overall survival (OS) in subgroups stratified by baseline ctDNA and log-fold change in ctDNA at EOT vs baseline. In biomarker-evaluable patients (n = 33), baseline ctDNA level correlated with serum lactate dehydrogenase (LDH) concentration, number of prior therapies, stage, and International Prognostic Index (IPI). After adjusting for number of prior therapies \u22652, IPI score \u22653, and LDH above the upper limit of normal, high (greater than median) baseline ctDNA MMPM was independently prognostic for shorter PFS (adjusted hazard ratio [HR], 0.18 [95% CI, 0.05-0.65]) and OS (adjusted HR, 0.20 [95% CI, 0.06-0.68]). In 23 patients with baseline and EOT samples, a significantly greater decrease in ctDNA MMPM was observed in patients with complete response (CR) (n = 13) than those without CR\u00a0(n = 10); P = .0025. Baseline ctDNA assessment may identify patients at high risk of progression and should be further evaluated as a monitoring tool in R\/R DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT02257567.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006415","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T23:03:28Z","timestamp":1643324608000},"page":"1651-1660","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"first","affiliation":[{"name":"City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7057-0832","authenticated-orcid":false,"given":"Samuel","family":"Tracy","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Croft","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"Clinical Haematology, Monash Health and Monash University, Clayton, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Ray","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Lovejoy","sequence":"additional","affiliation":[{"name":"Roche Sequencing Solutions, Pleasanton, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Musick","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-7139","authenticated-orcid":false,"given":"Joseph N.","family":"Paulson","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-9765","authenticated-orcid":false,"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"British Columbia (BC) Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"issue":"9","key":"2022031116284347700_B1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med."},{"issue":"6","key":"2022031116284347700_B2","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","article-title":"Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: target and linker-drug selection","volume":"69","author":"Polson","year":"2009","journal-title":"Cancer Res."},{"issue":"1","key":"2022031116284347700_B3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V81.1.84.84","article-title":"Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia\/non-Hodgkin\u2019s lymphoma and are effectively internalized after binding to the cell surface antigen","volume":"81","author":"Okazaki","year":"1993","journal-title":"Blood."},{"key":"2022031116284347700_B4","author":"U.S. Food and Drug Administration"},{"key":"2022031116284347700_B5","author":"EMA"},{"issue":"2","key":"2022031116284347700_B6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol."},{"issue":"28","key":"2022031116284347700_B7","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022031116284347700_B8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"issue":"23","key":"2022031116284347700_B9","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1200\/JCO.20.02573","article-title":"Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma","volume":"39","author":"Alig","year":"2021","journal-title":"J Clin Oncol."},{"key":"2022031116284347700_B10","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1200\/JCO.2019.37.15_suppl.7552","article-title":"Monitoring ctDNA in r\/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: day 28 landmark analysis","volume":"37","author":"Frank","year":"2019","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022031116284347700_B11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol."},{"issue":"364","key":"2022031116284347700_B12","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med."},{"issue":"2","key":"2022031116284347700_B13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)."},{"key":"2022031116284347700_B14","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1538-7445.AM2018-4574","article-title":"Detection of minimal residual disease from less than one cell equivalent in liquid biopsy samples using the AVENIO ctDNA Surveillance Kit","volume":"78","author":"Pati","year":"2018","journal-title":"Cancer Res."},{"issue":"11","key":"2022031116284347700_B15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood."},{"issue":"18","key":"2022031116284347700_B16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med."},{"issue":"1","key":"2022031116284347700_B17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjh.13389","article-title":"Response-adapted therapy for aggressive non-Hodgkin\u2019s lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)","volume":"170","author":"Swinnen","year":"2015","journal-title":"Br J Haematol."},{"issue":"2","key":"2022031116284347700_B18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2016.154039","article-title":"Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14","volume":"102","author":"Hertzberg","year":"2017","journal-title":"Haematologica."},{"issue":"8","key":"2022031116284347700_B19","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","article-title":"Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study","volume":"18","author":"Chiappella","year":"2017","journal-title":"Lancet Oncol."},{"key":"2022031116284347700_B20","first-page":"1600","article-title":"Interim circulating tumor DNA as a prognostic biomarker in the setting of interim PET-based adaptive therapy for DLBCL","volume":"134","author":"Macaulay","year":"2019","journal-title":"Am J Hematol."},{"issue":"19","key":"2022031116284347700_B21","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood."},{"issue":"1","key":"2022031116284347700_B22","doi-asserted-by":"crossref","first-page":"14814","DOI":"10.1038\/s41598-018-33230-3","article-title":"Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP","volume":"8","author":"Peroja","year":"2018","journal-title":"Sci Rep."},{"issue":"13","key":"2022031116284347700_B23","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood."},{"issue":"13","key":"2022031116284347700_B24","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv."},{"key":"2022031116284347700_B25","doi-asserted-by":"crossref","first-page":"103109","DOI":"10.1016\/j.critrevonc.2020.103109","article-title":"ctDNA as a cancer biomarker: a broad overview","volume":"155","author":"Pessoa","year":"2020","journal-title":"Crit Rev Oncol Hematol."},{"issue":"1","key":"2022031116284347700_B26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13148-016-0261-y","article-title":"Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma","volume":"8","author":"Kristensen","year":"2016","journal-title":"Clin Epigenetics."},{"issue":"7","key":"2022031116284347700_B27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ajh.24751","article-title":"Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma","volume":"92","author":"Wedge","year":"2017","journal-title":"Am J Hematol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/6\/1651\/1879524\/advancesadv2021006415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/6\/1651\/1879524\/advancesadv2021006415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:31:52Z","timestamp":1674606712000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/6\/1651\/483728\/Risk-profiling-of-patients-with-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,3,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006415","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}